Surmodics Inc. is poised to jump on the market for below the knee thrombectomy now that its Pounce platform with a low-profile (LP) model has FDA 510(k) clearance. The system can now effectively clear organized clots from vessels as small as 2 mm in diameter. The Pounce LP expands the Eden Prairie, Minn.-based company’s “grab-go-flow” platform. In its first iteration, Pounce enabled removal of thrombi and emboli in peripheral arteries 3.5 mm to 6 mm in diameter.

Surmodics Inc. has acquired Vetex Medical Ltd., a Galway, Ireland-based company focused on venous clot removal, for $39.9 million. The move gives Surmodics a second FDA-cleared mechanical thrombectomy device, Revene, to treat venous vasculature, adding to its Pounce arterial thrombus retrieval system. Founded in 2016, privately held Vetex’s sole product is the Revene thrombectomy catheter. The device received FDA clearance in December 2020 and CE mark approval in May for the mechanical declotting and controlled and selected infusion of physician-specified fluids, including thrombolytics – clot-busting drugs – in the peripheral vasculature.